Incyte upgraded to Buy from Hold at Stifel
Stifel upgraded Incyte (INCY) to Buy from Hold with a $107 price target
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms
Qiagen and Incyte have announced a master collaboration agreement to create a diagnostic panel to aid in the treatment of individuals with a group of rare blood cancers known as myeloproliferative neoplasms (MPNs). This partnership focuses on supporting Incyte's investigational therapies, including the monoclonal antibody INCA033989, which targets mutant calreticulin (mutCALR) in conditions such as myelofibrosis (MF) and essential thrombocythemia (ET). According to the agreement, Qiagen will create a multimodal panel leveraging next-generation sequencing (NGS) to detect clinically relevant gene alterations in haematological malignancies. The validation of the panel will be done by the Illumina NextSeq 550Dx platform as part of Qiagen's collaboration with the latter to provide NGS diagnostic platforms for global laboratory testing. Regulatory submissions and market access activities will be supported by Qiagen across the European Union, the US, and the Asia-Pacific regions. According to Qiagen, MPNs account for approximately 40% of haematological malignancies and are marked by the overproduction of various mature blood cells. Incyte research and development head and president Pablo Cagnoni said: 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with Qiagen, which will facilitate CALR testing for patients with MPNs on a global basis. 'The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF.' Incyte's INCA033989 for mutCALR ET or MF aims to eliminate malignant cells while sparing healthy ones. CALR is said to play a crucial role in managing calcium levels within cells and ensuring the production of proteins. Last month, Qiagen entered a commercial collaboration and joint marketing agreement with ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for applications in oncology research. "Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Insider
an hour ago
- Business Insider
TD Cowen Remains a Hold on Paychex (PAYX)
In a report released today, Bryan Bergin from TD Cowen maintained a Hold rating on Paychex (PAYX – Research Report), with a price target of $153.00. The company's shares closed last Friday at $153.22. Confident Investing Starts Here: Bergin covers the Technology sector, focusing on stocks such as Accenture, Cognizant, and Exlservice Holdings. According to TipRanks, Bergin has an average return of 2.5% and a 49.28% success rate on recommended stocks. Currently, the analyst consensus on Paychex is a Hold with an average price target of $169.14, which is a 10.39% upside from current levels. In a report released on June 10, Morgan Stanley also maintained a Hold rating on the stock with a $150.00 price target. PAYX market cap is currently $55.19B and has a P/E ratio of 31.86. Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PAYX in relation to earlier this year. Most recently, in April 2025, Michael Gioja, the SVP of PAYX sold 31,653.00 shares for a total of $4,893,136.23.
Business Insider
3 hours ago
- Business Insider
Oppenheimer Remains a Buy on Nurix Therapeutics (NRIX)
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) yesterday and set a price target of $32.00. The company's shares closed last Friday at $11.93. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Biegler is an analyst with an average return of -12.1% and a 31.68% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and Nurix Therapeutics. In addition to Oppenheimer, Nurix Therapeutics also received a Buy from Truist Financial's Srikripa Devarakonda in a report issued on June 13. However, on June 3, Leerink Partners reiterated a Hold rating on Nurix Therapeutics (NASDAQ: NRIX).
